EZH2 and gastric adenocarcinoma: More specifically, in the STAD group, the expression of RCAN1, IL1A, ALDH3B1, EZH2, EPAS1, PXDN, UCP3, PDGFRB, COL1A1, DHFR, GPX1, AIFM1, JAK2, HYAL2, EDNRA, GCH1, and NOS3 increased, while the expression of NR4A3, CD36, MSRB3, SOD3, CRYAB, SNCA, APOD, BNIP3, SCARA3, GPX3, and PRKAA2 were decreased (Figure 1A, P < 0.05).